Annalisa Trenti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annalisa Trenti has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Lucia Trevisi
Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Largo E. Meneghetti 2, 35131, Padua, Italy
5 shared publicationsChiara Bolego
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
4 shared publications- Angelo Sala
University of Milan
3 shared publications Carola Buccellati
Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133, Milan, Italy
3 shared publications- Lucia Trevisi
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo Meneghetti 2, 35131 Padova, Italy
3 shared publications Aldo R. Eynard
Instituto de Investigaciones en Ciencias de la Salud de Córdoba (INICSA-CONICET), Universidad Nacional de Córdoba, Enrique Barros s/n. Ciudad Universitaria, 5000, Córdoba, Argentina
2 shared publications
Latest Publications
- 11 August 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (18) , 3094-3106
Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors
Background and Purpose: Cardiac glycosides are Na+/K+‐ATPases inhibitors used to treat congestive heart failure and cardiac arrhythmias. Epidemiological studies indicate that patients on digitalis therapy are more protected from cancer. Evidence of a selective cytotoxicity against cancer cells has suggested their potential use as anticancer drugs. The effect on angiogenesis of clinically used cardiac glycosides has not been extensively explored.Experimental Approach: We studied the effect of digoxin, digitoxin and ouabain on early events of the angiogenic process in HUVECs. We determined HUVEC viability, proliferation, migration and differentiation into capillary tube‐like structures. We also tested drug activity using an in vivo angiogenesis model. Activation of protein tyrosine kinase 2 (FAK) and signalling proteins associated with the Na+/K+‐ATPase signalosome was determined by Western blotting.Key Results: Digitoxin and ouabain (1–100 nM) inhibited HUVEC migration, concentration‐dependently, without affecting cell viability, while digoxin induced apoptosis at the same concentrations. Digitoxin antagonized growth factor‐induced migration and tubularization at concentrations (1–25 nM) within its plasma therapeutic range. The anti‐angiogenic effect of digitoxin was confirmed also by in vivo studies. Digitoxin induced Src, Akt and ERK1/2 phosphorylation but did not affect FAK autophosphorylation at Tyr397. However, it significantly inhibited growth factor‐induced FAK phosphorylation at Tyr576/577.Conclusions and Implications: Therapeutic concentrations of digitoxin inhibited angiogenesis and FAK activation by several pro‐angiogenic stimuli. These novel findings suggest a potential repositioning of digitoxin as a broad‐spectrum anti‐angiogenic drug for diseases where pathological angiogenesis is involved.
- 11 August 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (18) , 3094-3106
Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors
Background and Purpose: Cardiac glycosides are Na+/K+‐ATPases inhibitors used to treat congestive heart failure and cardiac arrhythmias. Epidemiological studies indicate that patients on digitalis therapy are more protected from cancer. Evidence of a selective cytotoxicity against cancer cells has suggested their potential use as anticancer drugs. The effect on angiogenesis of clinically used cardiac glycosides has not been extensively explored.Experimental Approach: We studied the effect of digoxin, digitoxin and ouabain on early events of the angiogenic process in HUVECs. We determined HUVEC viability, proliferation, migration and differentiation into capillary tube‐like structures. We also tested drug activity using an in vivo angiogenesis model. Activation of protein tyrosine kinase 2 (FAK) and signalling proteins associated with the Na+/K+‐ATPase signalosome was determined by Western blotting.Key Results: Digitoxin and ouabain (1–100 nM) inhibited HUVEC migration, concentration‐dependently, without affecting cell viability, while digoxin induced apoptosis at the same concentrations. Digitoxin antagonized growth factor‐induced migration and tubularization at concentrations (1–25 nM) within its plasma therapeutic range. The anti‐angiogenic effect of digitoxin was confirmed also by in vivo studies. Digitoxin induced Src, Akt and ERK1/2 phosphorylation but did not affect FAK autophosphorylation at Tyr397. However, it significantly inhibited growth factor‐induced FAK phosphorylation at Tyr576/577.Conclusions and Implications: Therapeutic concentrations of digitoxin inhibited angiogenesis and FAK activation by several pro‐angiogenic stimuli. These novel findings suggest a potential repositioning of digitoxin as a broad‐spectrum anti‐angiogenic drug for diseases where pathological angiogenesis is involved.
- 1 August 2017
- Published by Elsevier in Pharmacological Research
- Vol. 122, 96-104
Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1
- 1 August 2017
- Published by Elsevier in Pharmacological Research
- Vol. 122, 96-104
Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1
- 1 June 2017
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 361 (3) , 398-407
The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1
The endogenous estrogen 17β-estradiol (E2) is a key factor in promoting endothelial healing and angiogenesis. Recently, proangiogenic signals including vascular endothelial growth factor and others have been shown to converge in endothelial cell metabolism. Because inhibition of the glycolytic enzyme activator phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) reduces pathologic angiogenesis and estrogen receptor (ER) signaling stimulates glucose uptake and glycolysis by inducing PFKFB3 in breast cancer, we hypothesized that E2 triggers angiogenesis in endothelial cells via rapid ER signaling that requires PFKFB3 as a downstream effector. We report that treatment with the selective G protein-coupled estrogen receptor (GPER1) agonist G-1 (10−10 to 10−7 M) mimicked the chemotactic and proangiogenic effect of E2 as measured in a number of short-term angiogenesis assays in human umbilical vein endothelial cells (HUVECs); in addition, E2 treatment upregulated PFKFB3 expression in a time- and concentration-dependent manner. Such an effect peaked at 3 hours and was also induced by G-1 and abolished by pretreatment with the GPER1 antagonist G-15 or GPER1 siRNA, consistent with engagement of membrane ER. Experiments with the PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one showed that PFKFB3 activity was required for estrogen-mediated HUVEC migration via GPER1. In conclusion, E2-induced angiogenesis was mediated at least in part by the membrane GPER1 and required upregulation of the glycolytic activator PFKFB3 in HUVECs. These findings unravel a previously unrecognized mechanism of estrogen-dependent endocrine-metabolic crosstalk in HUVECs and may have implications in angiogenesis occurring in ischemic or hypoxic tissues.
- 1 June 2017
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 361 (3) , 398-407
The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1
The endogenous estrogen 17β-estradiol (E2) is a key factor in promoting endothelial healing and angiogenesis. Recently, proangiogenic signals including vascular endothelial growth factor and others have been shown to converge in endothelial cell metabolism. Because inhibition of the glycolytic enzyme activator phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) reduces pathologic angiogenesis and estrogen receptor (ER) signaling stimulates glucose uptake and glycolysis by inducing PFKFB3 in breast cancer, we hypothesized that E2 triggers angiogenesis in endothelial cells via rapid ER signaling that requires PFKFB3 as a downstream effector. We report that treatment with the selective G protein-coupled estrogen receptor (GPER1) agonist G-1 (10−10 to 10−7 M) mimicked the chemotactic and proangiogenic effect of E2 as measured in a number of short-term angiogenesis assays in human umbilical vein endothelial cells (HUVECs); in addition, E2 treatment upregulated PFKFB3 expression in a time- and concentration-dependent manner. Such an effect peaked at 3 hours and was also induced by G-1 and abolished by pretreatment with the GPER1 antagonist G-15 or GPER1 siRNA, consistent with engagement of membrane ER. Experiments with the PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one showed that PFKFB3 activity was required for estrogen-mediated HUVEC migration via GPER1. In conclusion, E2-induced angiogenesis was mediated at least in part by the membrane GPER1 and required upregulation of the glycolytic activator PFKFB3 in HUVECs. These findings unravel a previously unrecognized mechanism of estrogen-dependent endocrine-metabolic crosstalk in HUVECs and may have implications in angiogenesis occurring in ischemic or hypoxic tissues.
- 28 March 2016
- Published by Springer Nature in European Journal of Nutrition
- Vol. 55 (4) , 1809
Erratum to: Increased dietary levels of α-linolenic acid inhibit mammary tumor growth and metastasis
- 28 March 2016
- Published by Springer Nature in European Journal of Nutrition
- Vol. 55 (4) , 1809
Erratum to: Increased dietary levels of α-linolenic acid inhibit mammary tumor growth and metastasis
- 18 November 2015
- Published by Springer Nature in European Journal of Nutrition
- Vol. 56 (2) , 509-519
Increased dietary levels of α-linoleic acid inhibit mammary tumor growth and metastasis
Objective The aim of this study was to determine whether α-linolenic acid (ALA ω-3 fatty acid) enriched diet affects growth parameters when applied to a syngeneic model of mammary carcinoma. Materials and methods BALB/c mice were divided and fed with: 1) a chia oil diet, rich in ALA or 2) a corn oil diet, rich in linoleic acid (LA ω-6 fatty acid). Mice were subcutaneously inoculated with a tumor cell line LM3, derived from a murine mammary adenocarcinoma. Results After 35 days, tumor incidence, weight, volume and metastasis number were lower in the ALA-fed mice, while tumor latency time was higher, and the release of pro-tumor metabolites derived from ω-6 fatty acids decreased in the tumor. Compared to the control group, a lower number of mitosis, a higher number of apoptotic bodies and higher T-lymphocyte infiltration were consistently observed in the ALA group. An ALA-rich diet decreased the estrogen receptor (ER) α expression, a recognized breast cancer promotor while showing an opposite effect on ERβ in tumor lysates. Conclusion These data support the anticancer effect of an ALA-enriched diet, which might be used as a dietary strategy in breast cancer prevention.
- 18 November 2015
- Published by Springer Nature in European Journal of Nutrition
- Vol. 56 (2) , 509-519
Increased dietary levels of α-linoleic acid inhibit mammary tumor growth and metastasis
Objective The aim of this study was to determine whether α-linolenic acid (ALA ω-3 fatty acid) enriched diet affects growth parameters when applied to a syngeneic model of mammary carcinoma. Materials and methods BALB/c mice were divided and fed with: 1) a chia oil diet, rich in ALA or 2) a corn oil diet, rich in linoleic acid (LA ω-6 fatty acid). Mice were subcutaneously inoculated with a tumor cell line LM3, derived from a murine mammary adenocarcinoma. Results After 35 days, tumor incidence, weight, volume and metastasis number were lower in the ALA-fed mice, while tumor latency time was higher, and the release of pro-tumor metabolites derived from ω-6 fatty acids decreased in the tumor. Compared to the control group, a lower number of mitosis, a higher number of apoptotic bodies and higher T-lymphocyte infiltration were consistently observed in the ALA group. An ALA-rich diet decreased the estrogen receptor (ER) α expression, a recognized breast cancer promotor while showing an opposite effect on ERβ in tumor lysates. Conclusion These data support the anticancer effect of an ALA-enriched diet, which might be used as a dietary strategy in breast cancer prevention.
- 1 September 2015
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 121, 190-198
Antiinflammatory and antioxidant effects of H2O2 generated by natural sources in Il1β-treated human endothelial cells
- 1 September 2015
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 121, 190-198
Antiinflammatory and antioxidant effects of H2O2 generated by natural sources in Il1β-treated human endothelial cells
- 3 August 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (18) , 4575-4587
Dysregulated post‐transcriptional control ofCOX‐2 gene expression in gestational diabetic endothelial cells
Background and Purpose: Hyperglycaemic memory describes the progression of diabetic complications during subsequent periods of improved glycaemia. We addressed the hypothesis that transient hyperglycaemia causes aberrantCOX‐2 expression inHUVECin response toIL‐1β through the induction of long‐lasting epigenetic changes involving microRNA‐16 (miR‐16), a post‐transcriptional modulator ofCOX‐2 expression.Experimental Approach: Studies were performed onHUVECcollected from women with gestational diabetes mellitus (GDM) (dHUVEC) and normal women (nHUVEC).Key Results: IndHUVECtreated withIL‐1β, the expression ofCOX‐2mRNAand protein was enhanced and generation of prostanoids increased (the most abundant was the promitogenicPGF2α).COX‐2mRNAwas more stable indHUVECand this was associated with miR‐16 down‐regulation and c‐Myc induction (a suppressor of miRexpression).dHUVECshowed increased proliferation in response toIL‐1β, which was prevented by aCOX‐2 inhibitor andPGF2αreceptor antagonist. Comparable changes inCOX‐2mRNA, miR‐16 and c‐Myc detected indHUVECwere produced innHUVECexposed to transient high glucose and then stimulated withIL‐1β under physiological glucose levels; superoxide anion production was enhanced under these experimental conditions.Conclusions and Implications: Our results describe a possible mechanism operating inGDMthat links the enhanced superoxide anion production and epigenetic changes, associated with hyperglycaemic memory, to endothelial dysfunction through dysregulated post‐transcriptional control ofCOX‐2 gene expression in response to inflammatory stimuli. The association of conventional therapy for glycaemic control with agents affecting inflammatory responses and oxidative stress might lead to a more effective prevention of the complications associated withGDM.
- 3 August 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (18) , 4575-4587
Dysregulated post‐transcriptional control ofCOX‐2 gene expression in gestational diabetic endothelial cells
Background and Purpose: Hyperglycaemic memory describes the progression of diabetic complications during subsequent periods of improved glycaemia. We addressed the hypothesis that transient hyperglycaemia causes aberrantCOX‐2 expression inHUVECin response toIL‐1β through the induction of long‐lasting epigenetic changes involving microRNA‐16 (miR‐16), a post‐transcriptional modulator ofCOX‐2 expression.Experimental Approach: Studies were performed onHUVECcollected from women with gestational diabetes mellitus (GDM) (dHUVEC) and normal women (nHUVEC).Key Results: IndHUVECtreated withIL‐1β, the expression ofCOX‐2mRNAand protein was enhanced and generation of prostanoids increased (the most abundant was the promitogenicPGF2α).COX‐2mRNAwas more stable indHUVECand this was associated with miR‐16 down‐regulation and c‐Myc induction (a suppressor of miRexpression).dHUVECshowed increased proliferation in response toIL‐1β, which was prevented by aCOX‐2 inhibitor andPGF2αreceptor antagonist. Comparable changes inCOX‐2mRNA, miR‐16 and c‐Myc detected indHUVECwere produced innHUVECexposed to transient high glucose and then stimulated withIL‐1β under physiological glucose levels; superoxide anion production was enhanced under these experimental conditions.Conclusions and Implications: Our results describe a possible mechanism operating inGDMthat links the enhanced superoxide anion production and epigenetic changes, associated with hyperglycaemic memory, to endothelial dysfunction through dysregulated post‐transcriptional control ofCOX‐2 gene expression in response to inflammatory stimuli. The association of conventional therapy for glycaemic control with agents affecting inflammatory responses and oxidative stress might lead to a more effective prevention of the complications associated withGDM.
- 1 July 2015
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 120, 103-114
Dysregulation of gene expression in human fetal endothelial cells from gestational diabetes in response to TGF-β1
- 1 July 2015
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 120, 103-114
Dysregulation of gene expression in human fetal endothelial cells from gestational diabetes in response to TGF-β1
- Open Access
- 1 January 2015
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 7 (11) , 1497-1507
Homoleptic phosphino copper(i) complexes with in vitro and in vivo dual cytotoxic and anti-angiogenic activity
A series of homoleptic phosphino copper(i) complexes inhibit cancer cell growth and angiogenesis in cultured cells and in animal models.
- 1 January 2015
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 7 (11) , 1497-1507
Open AccessHomoleptic phosphino copper(i) complexes with in vitro and in vivo dual cytotoxic and anti-angiogenic activity
A series of homoleptic phosphino copper(i) complexes inhibit cancer cell growth and angiogenesis in cultured cells and in animal models.
- 1 May 2014
- Published by Elsevier in Biochemical Pharmacology
- Vol. 89 (2) , 197-209
Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2
- 1 May 2014
- Published by Elsevier in Biochemical Pharmacology
- Vol. 89 (2) , 197-209
Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2